7 results about "Idarubicin" patented technology

1. Name of the product of this design: Packaging box (Idarubicin and Dextromethorphan Sublingual Tablets - Xinbixin). 2. Purpose of this design product: This design product is used for pharmaceutical packaging. 3. The key design points of this product are the combination of shape, pattern and color. 4. The picture or photo that best illustrates the key points of the design: main view. 5. The design for which protection is sought includes color.

A pharmaceutical composition for preventing and / or treating tumors, which pharmaceutical composition contains the following topoisomerase II inhibitors as active ingredients: doxorubicin, etoposide, idarubicin, amsacrine, aclarubicin, teniposide, epirubicin, and pirarubicin. The pharmaceutical composition, compared with any one of the components therein, has significantly enhanced tumor inhibitory effects and significantly reduced toxic side effects, wherein a synergistic effect is present among the components.

The invention discloses a pharmaceutical composition containing a polysialic acid-melittin polyion compound and sialic acid modified anthracycline anti-tumor drug liposome and application of the pharmaceutical composition. The invention belongs to the technical field of biological medicine, and particularly relates to a targeted delivery pharmaceutical composition for treating cold tumors through immunotherapy, and the pharmaceutical composition comprises a polysialic acid-melittin polyion compound and sialic acid modified anthracycline antitumor drug liposome. The anthracycline antitumor drug is selected from one or more of the following components: doxorubicin, epirubicin, pirarubicin, idarubicin, daunorubicin or mitoxantrone. The pharmaceutical composition shows a remarkable synergistic effect in tumor inhibition index, can stimulate congenital immunity and adaptive immunity, induce multiple release of tumor-associated antigens and specific antigens, trigger tumor immune circulation and recover immune control of a body on tumors, and also can enable the body to generate immune memory, so that the tumor inhibition effect is improved. And a new combined treatment strategy is provided for cold tumor treatment.

The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicine. The invention discloses application of idarubicin in preparation of a medicine for treating benign prostatic hyperplasia. The application of idarubicin in BPH treatment is found and confirmed for the first time: (1) the specificity effectiveness of BPH, preferably gland proliferation type BPH, is verified, and the intervention effect of idarubicin on a core target TP63 and gland proliferation is clear; (2) the regulation and control effect on prostate volume and gland hyperplasia is supported through in-vivo experimental data; and (3) curative effect verification at a clinical level is carried out, and a clinical application path of subtype screening-drug intervention-curative effect evaluation is established, so that transformation in BPH precise treatment is facilitated. According to the research, through a complete evidence chain of cell, animal and multi-center clinical retrospective research, the treatment value of idarubicin on BPH, especially gland proliferation type BPH, is verified, and the blank in the field is filled.

The invention relates to the technical field of drugs for acute organ injury, and particularly discloses idebenone-modified platelet membrane-coated mitochondria as well as a preparation method and application thereof, aiming at the problems of low drug delivery efficiency, insufficient targeting and the like of ROS (reactive oxygen species) removal drugs for acute organ injury at present. The in-vitro mitochondria-modified platelet membrane comprises in-vitro mitochondria and an idebenone-modified platelet membrane coating the in-vitro mitochondria, the preparation method comprises the following steps: S1, extracting a platelet membrane; s2, extracting mitochondria; s3, mixing the platelet membrane with mitochondria, and centrifuging for multiple times to obtain platelet membrane coated mitochondria; and S4, incubating and combining the platelet membrane-coated mitochondria with idebenone, carrying out centrifugal washing for multiple times, adding a lysis solution, and carrying out lysis, ultrasonication and separation to obtain the idebenone-modified platelet membrane-coated mitochondria. A platelet membrane is modified by idebenone, a mitochondrial targeting delivery system is constructed and directly acts on active oxygen in cells, and the pertinence and efficiency of therapeutic drugs are improved.

The invention relates to a pharmaceutical composition for preventing and / or treating tumors. The pharmaceutical composition comprises the following topoisomerase II inhibitors as active ingredients: doxorubicin, etoposide, idarubicin, anacridine, acarubicin, teniposide, epirubicin and pirarubicin. Compared with any one of the components, the pharmaceutical composition disclosed by the invention has a remarkable tumor inhibition effect, the toxic and side effects are obviously reduced, and all the components have a synergistic effect.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.